You are here: Industry Insights > NVX-CoV2373

News List

FUJIFILM Diosynth Hosts UK PM at COVID Vax Mfg. Site contractpharma
February 18, 2021
Billingham site to support the manufacture of up to 180 million doses Novavax’ NVX-CoV2373 COVID-19 vaccine candidate.
Novavax, SK Bioscience Expand Vax Pact contractpharma
February 18, 2021
The existing partnership for manufacture of NVX-CoV2373 has been expanded to increase production capacity and supply vaccines to the Korean Government.
Multiple rolling reviews kick-off for Novavax’s COVID-19 vaccine pharmatimes
February 05, 2021
Rolling reviews of Novavax’s COVID-19 vaccine have kicked-off in the UK, US, EU and Canada following the recent announcement that the jab demonstrated 89.3% efficacy in a phase III trial.
Baxter, Novavax Ink Sterile Manufacturing Agreement contractpharma
January 12, 2021
CMO Baxter will help increase commercial production and promote access to Novavax' Covid-19 vax in UK and European markets.
Novavax announces initiation of PREVENT-19 pivotal Phase 3 efficacy trial of COVID-19 vaccine in the United States and Mexico worldpharmanews
December 29, 2020
Novavax, Inc. announced initiation of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373, the Company's COVID-19 vaccine candidate.
FDA grants Fast Track Designation to Novavax COVID-19 vaccine candidate europeanpharmaceuticalreview
November 13, 2020
The FDA has given Fast Track Designation to NVX-CoV2373, Novavax’s COVID-19 vaccine candidate, created using recombinant nanoparticle technology.
Novavax COVID-19 vaccine granted Fast Track Designation by U.S. FDA worldpharmanews
November 11, 2020
Novavax, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for NVX-CoV2373, the Company’s COVID-19 vaccine candidate.
Australia to acquire 40 million doses of Novavax Covid-19 vaccine pharmaceutical-technology
November 06, 2020
Novavax has signed a non-binding heads of terms document with the Australian Government to supply 40 million doses of its Covid-19 vaccine candidate, NVX-CoV2373.
Novavax provides Phase 3 COVID-19 vaccine clinical development update worldpharmanews
October 29, 2020
Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19 vaccine candidate.
Second wave of COVID-19 vaccines may not be needed to reach higher efficacy bar than first batch expresspharma
October 26, 2020
It would be best for second wave vaccines to underscore ideal subpopulations or manufacturing and storage advantages that could underscore uptake.

Previous page 1 2 3 4 5 6 7 Next page